Last updated: July 30, 2026
Yosprala (Aspirin + Omeprazole) Clinical Trials Update, FDA Status, Market Forecast and Patent Expiry Risks
Executive summary: Yosprala (fixed-dose aspirin 81 mg/omeprazole 40 mg delayed-release) is positioned as a gastroprotection-plus-antiplatelet regimen for patients needing aspirin. Public clinical-trials activity is limited and centered on comparability, bioequivalence and on-therapy outcomes rather than new efficacy phase programs. Market trajectory is driven by label adoption in secondary cardiovascular prevention and penetration versus generic aspirin plus generic PPIs, with price and contracting determining durability. From an exclusivity perspective, commercial runway is primarily tied to listed Orange Book patents and any unexpired exclusivities tied to NDA approvals or marketing authorizations; competitive entry pressure increases as those rights approach expiration, especially for combination products where generics can pair approved aspirin and PPI ingredients if formulation and method claims do not bar.
What clinical trials have been run for Yosprala (aspirin/omeprazole) and what are the latest results?
Bottom line: The core evidence base for Yosprala is built on pharmacokinetic and clinical comparability to concomitant aspirin and omeprazole, with gastroesophageal safety endpoints supporting the gastroprotection rationale. Recent “updates” for Yosprala tend to be post-approval studies and label-maintenance work rather than new large phase-3 outcome trials.
Which studies define Yosprala’s efficacy and safety package?
Key trial archetypes typically include:
- Bioequivalence and pharmacokinetic bridging for the fixed-dose combination formulation (timing of delayed release and absorption overlap).
- Safety assessments focused on gastrointestinal (GI) events, including dyspepsia and ulcer risk.
- On-therapy adherence and tolerability compared with taking aspirin plus a PPI as separate products.
What endpoint improvements matter commercially?
For payer adoption, “clinical update” translates into:
- Reduced GI adverse events relative to aspirin alone (where studied or inferred through bridging to known aspirin GI risk).
- Lower need for rescue therapy such as additional acid suppression.
- Simplification of dosing compared with separate pill regimens.
Are there new phase-3 cardiovascular outcome trials?
No public signal suggests large, new cardiovascular outcomes programs for Yosprala comparable to primary antiplatelet efficacy trials for aspirin itself; the combination is intended as a GI-protection strategy around established aspirin benefit.
What is the FDA regulatory status of Yosprala and is it Orange Book listed?
Bottom line: Yosprala is an FDA-approved fixed-dose combination product (aspirin enteric formulation with omeprazole delayed release). Its enforceable IP landscape depends on its Orange Book listings covering product composition, formulation, and/or methods of use, plus any relevant exclusivities associated with approval.
What does the Orange Book cover for Yosprala?
Orange Book typically includes:
- Drug substance or drug product patents for composition/ingredient-related claims.
- Formulation or method-of-use patents tied to the fixed-dose unit.
- Expiration dates and patent term information that define generic entry timing.
What FDA pathway would generics use if patents expire?
Common scenarios for combination products:
- ANDA with Paragraph IV certifications to listed patents if formulation or method claims do not block entry.
- Section viii carve-outs depend on whether the applicant can maintain equivalent release characteristics and labeling claims.
- Entry can still be delayed by enforceable method-of-use patents even if composition patents are weak.
What label scope affects payer uptake and generic substitution?
Label wording around:
- Patients who require aspirin therapy and have increased GI risk.
- Indication language that pairs “aspirin plus omeprazole gastroprotection” can influence how aggressively biosimilar/generic-like substitutions are attempted through prescribing patterns.
When does Yosprala lose exclusivity and when do patents expire?
Bottom line: The decisive timeline is the set of Orange Book patent expirations plus any granted exclusivity periods. As those dates near, the generic risk curve rises quickly because Paragraph IV challenges tend to accelerate at scale when multiple listed patents approach expiration.
How to read Yosprala exclusivity risk for market projection
Use a two-layer model:
- Patent cliffs: the earliest expiration among the most relevant Orange Book patents (often formulation or method-of-use).
- Hard-to-design-around claims: method-of-use and release-profile formulation claims that can require litigation or costly reformulation.
Market projection sensitivity to patent expiry
- Before earliest expiration: low competitive threat if multiple patents remain listed and enforceable.
- 0 to 24 months before expiration: payers start “pre-bundling” alternatives and pressure pricing.
- Post-expiration window: generic substitution can be rapid if claims are narrow or settled early, but slower if injunction risk exists.
What patents protect Yosprala (aspirin/omeprazole) and how strong is the patent estate?
Bottom line: The patent estate for a fixed-dose aspirin/omeprazole product usually concentrates on formulation design (release timing and unit dosing) and method-of-use (gastroprotection with aspirin). Patent strength determines whether generics can enter via ANDA without redesign.
Which patent categories most influence generic entry?
For combination delayed-release aspirin and delayed-release omeprazole:
- Formulation patents: ratios and assembly rules to maintain delayed release performance.
- Method-of-use patents: prescribing regimen claims tying omeprazole administration to aspirin therapy for GI protection.
- Process/manufacturing patents: granulation, layering, or coating steps that preserve release characteristics.
How does patent strength map to settlement probability?
- Strong, clear composition/formulation claims increase odds of early settlements and authorized generics.
- Weak or easily designed-around claims increase odds that a generic files Paragraph IV without settlement.
What Paragraph IV challenges exist for Yosprala and how do they affect generic launch risk?
Bottom line: Generic entry risk is determined by whether ANDA applicants filed Paragraph IV certifications against listed patents and whether litigation produced settlements, carve-outs, or final judgments.
What to look for in Yosprala Paragraph IV litigation
Key litigation markers:
- Listing of the defendant ANDA applicant(s).
- Which patents were attacked (numbers and claim type).
- Court outcomes and any agreed launch dates.
How litigation outcomes change the market forecast
- Settlements with delayed entry: protect brand revenue into the agreed launch date.
- Court wins/entry design success: accelerate generic erosion and margin compression.
- Partial wins/carve-outs: limit substitution to specific label populations or dosing strengths.
What is the competitive landscape for Yosprala versus aspirin plus generic PPIs?
Bottom line: The main commercial competitor is not another branded fixed-dose product; it is the ability for patients and prescribers to use generic aspirin plus generic omeprazole or other PPIs as separate products. Yosprala’s differentiation is adherence and simplified dosing, and its pricing must compensate for lost flexibility.
Price and contracting drive real-world share
Yosprala performance typically hinges on:
- Formulary position in cardiovascular prevention or GI risk categories.
- PBM step edits (requiring separate PPIs first unless fixed-dose combination is preferred).
- Copay assistance effectiveness relative to low-cost generics.
Where does Yosprala win clinically or operationally?
- Patients with complex med regimens where pill burden increases nonadherence risk.
- Settings where a single prescription improves persistence.
How will biosimilar risk apply to Yosprala?
Bottom line: Biosimilar risk does not apply because Yosprala is a small-molecule fixed-dose combination (not biologics). Market risk comes from ANDA generics and authorized generics, not biosimilars.
What generic entry scenarios are most likely for Yosprala after patent expiry?
Bottom line: The most likely post-expiration outcomes are:
- Rapid ANDA launch of a fixed-dose aspirin/omeprazole equivalent (if formulation and method claims are not blocking).
- Slower launch but with generic-like access via separate generic aspirin plus omeprazole, which reduces Yosprala incremental value.
- Settlement-driven launch date that delays fixed-dose combination substitution.
Launch scenario modeling for revenue erosion
Market projection should incorporate three adoption curves:
- Formulary switching: how quickly PBMs remove Yosprala.
- Prescriber inertia: whether clinicians keep patients on the fixed-dose product.
- Member cost share: generic copays versus brand tiers.
What is the market projection for Yosprala through exclusivity and post-generic entry?
Bottom line: Yosprala’s addressable market is secondary prevention patients on aspirin who are perceived to have increased GI risk or require prophylaxis, but the combination faces structural price competition from generic aspirin + generic PPI regimens. Revenue can hold up pre-expiry if formulary placements remain stable; post-entry, the combination typically suffers steep share loss if fixed-dose generics appear.
Market sizing inputs that drive projections
Projections should use:
- Number of aspirin-treated cardiovascular patients (secondary prevention).
- Percent with GI risk or guideline-concordant gastroprotection.
- Formulary access rates and PBM tiering intensity.
- Net price after rebates and discounts.
Scenario table: 3-path projection
| Scenario |
Patent / litigation outcome |
Expected competitive response |
Revenue trend (directional) |
| Base |
No effective fixed-dose ANDA until later |
Brand pricing pressure but limited substitution |
Slower decline, possible plateau |
| Downside |
Earlier Paragraph IV wins or fast fixed-dose ANDA launches |
Rapid share erosion, higher PBM switching |
Steep decline after first generic |
| Upside |
Settlements delay generic launch; authorized generic limited |
Brand holds share longer, managed competition |
Gradual decline, longer runway |
What is Yosprala’s commercial adoption outlook by payer channel?
Bottom line: Adoption depends on PBM formulary placement and medical-necessity criteria, since the clinical value is primarily gastroprotection and convenience rather than a new antiplatelet mechanism.
Hospital and clinic contracting
- Specialty cardiology and internal medicine clinics may prescribe fixed-dose combinations to reduce medication errors.
- Many institutions shift to separate generic components if formularies favor lowest net cost.
Retail pharmacy channel
- Patient co-pay sensitivity matters most if brand tiering increases cost share.
- Co-pay support can extend persistence until PBM restrictions tighten.
How does Yosprala compare with other aspirin plus gastroprotection products?
Bottom line: Fixed-dose aspirin/omeprazole competes against:
- Separate aspirin and PPI regimens (principal competitor).
- Any branded or fixed-dose alternatives within aspirin gastroprotection classes (depending on market availability).
Key differentiators that affect substitution
- Release timing and formulation equivalence.
- Label specifics: who should receive combination therapy and under what GI risk profile.
- Cost-effectiveness versus separate generics in PBM contracting.
What manufacturing and formulation risks could block generic entry for Yosprala?
Bottom line: Fixed-dose delayed-release combinations can be protected by formulation and manufacturing know-how that ensures consistent release profiles. Even if active ingredients are generic-available, design-to-release alignment can be a technical and regulatory hurdle.
Where formulation risk shows up in ANDA development
- Demonstrating equivalent dissolution and delayed-release performance.
- Ensuring stability of the aspirin component within the unit-dose design.
- Bridging for GI protection claims tied to labeling.
Key Takeaways
- Yosprala’s clinical evidence is built around gastroprotection and fixed-dose formulation comparability rather than new blockbuster phase-3 cardiovascular efficacy.
- Market outcomes are dominated by PBM formularies and the structural substitution threat from generic aspirin plus generic PPIs.
- The highest-impact variables for revenue projection are the Orange Book patent expiration schedule, any Paragraph IV litigation outcomes, and settlement terms that set a fixed-dose combination launch date.
- Biosimilar risk is not applicable; competitive risk is ANDA generics and authorized generics, with formulation design and method-of-use claims determining launch timing.
FAQs
- What Orange Book patents are listed for Yosprala and which are most likely to be challenged in Paragraph IV filings?
- How quickly do PBMs typically switch cardiovascular gastroprotection patients from branded aspirin/omeprazole fixed-dose products to separate generic aspirin plus PPIs after generic entry?
- Does Yosprala’s fixed-dose delayed-release formulation create additional regulatory hurdles for ANDA applicants beyond bioequivalence?
- What settlement structures are most common for aspirin/omeprazole combination products when litigation involves formulation or method-of-use patents?
- How do prescribing restrictions or prior authorization policies influence Yosprala uptake in secondary prevention with GI risk?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Studies for “Yosprala” and “aspirin omeprazole.” U.S. National Library of Medicine.
